National Bank Sticks to Its Buy Rating for Rogers Communication (RCI)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Shine is a 3-star analyst with an average return of 3.3% and a 50.19% success rate. Shine covers the Communication Services sector, focusing on stocks such as BCE, Rogers Communication, and Telus.
In addition to National Bank, Rogers Communication also received a Buy from TR | OpenAI – 4o's Dialyn Tone in a report issued yesterday. However, today, Barclays maintained a Hold rating on Rogers Communication (NYSE: RCI).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness
We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They are also worried about the patent expiration of the firm's mega cancer drug KEYTRUDA and wondering whether Merck & Co., Inc. (NYSE:MRK) will be able to follow up with an equally successful successor. However, the shares did gain 3% this week after Pfizer announced that its bladder cancer drug PADCEV improves survival rates when paired with KEYTRUDA. Cramer was impressed as he commented: 'Look at Merck. I mean, Saint Merck. What a tough, what a tough.' Photo by National Cancer Institute on Unsplash Here are his earlier comments about Merck & Co., Inc. (NYSE:MRK): 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer
We recently published . Salesforce, Inc. (NYSE:CRM) is one of the stocks Jim Cramer recently discussed. Salesforce, Inc. (NYSE:CRM)'s shares have lost 28% year-to-date as the firm has struggled to retain investor attention in the age of AI. Like investors are hawkishly watching its revenue pipeline and revenue commitments for the rest of the year – a fact which led the stock to dip 5% in May after its fiscal first quarter earnings. Cramer discussed the sentiment surrounding enterprise software stocks and CEO Marc Benioff's attempts to counter it: '. . .and I think that people should recognize that these companies are all being viewed as, let's say carrion, because what's happened is this that you can develop your own stuff that is better. Now Marc Benioff is doing some pushback on that by the way, he's saying that if you're doing process stuff, you're not going to be able to, maybe creative, that would be Adobe. But not, Salesforce. So Marc's pushing back Salesforce. . .' Pixabay/Public Domain Here are his previous remarks about Salesforce, Inc. (NYSE:CRM): 'Okay, so Salesforce is a little tough right now because right now, the enterprise software companies are all coming down. I have not been recommending the stock hard. I want to see what happens with the quarter. I wish I could be more definite, but sometimes it's better just to say I don't have a handle on it.' While we acknowledge the potential of CRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer
We recently published . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)'s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck's well-known cancer treatment, KEYTRUDA. The gains were a much-needed boost to the stock, which is still down by 5.6% year-to-date, as the firm has struggled to grow revenue in a turnaround effort led by CEO Albert Bourla. Cramer lamented that Pfizer Inc. (NYSE:PFE)'s stock didn't move higher on the news: 'Bladder cancer. Now that is left over from the Seagen. The Seagen deal, that was supposed to be very, very important. They spent a fortune on Seagen. And I thought the [inaudible] I thought would be a little more just positive. People are not buying the stock. People just feel like, Pfizer comes up with good thing, good thing, good thing, and no one seems to, David, take it as gospel.' Copyright: kadmy / 123RF Stock Photo Cramer discussed Pfizer Inc. (NYSE:PFE) ahead of its earnings: 'There's another one, that I'm not so sure of, reporting at the same time, though, Pfizer. We need to see some really dramatic results here from the clinical trials like the ones that Pfizer picked up when they bought the Seagen at the end of 2023. It's enough time to see more than we've seen already, I gotta tell you that. And they better hurry up because the shareholder base is getting very restive, and who knows what the president has… against this industry.' While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
